A B S T R A C T A dopaminergic mechanism has been proposed to suppress aldosterone secretion. To assess the possibility that a defect in the dopaminergic mechanism might enhance aldosterone secretion in hypertensive patients, we determined basal and adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone (PA), cortisol, renin activity, and potassium concentrations before and during dopamine receptor stimulation with dopamine infusion and bromocriptine administration and dopamine receptor blockade with metoclopramide. The patient study groups included: (a) seven patients with low-renin hypertension and abnormal aldosterone suppression with sodium loading and presumed bilateral zona glomerulosa hyperplasia (ZGHP); (b) two patients with aldosterone-producing adenoma; (c) five patients with low-renin hypertension but normal aldosterone suppression with sodium loading; and (d) six patients with normal-renin hypertension.
INTRODUCTION
A dopaminergic influence on aldosterone secretion has been suggested by the observation that administration of metoclopramide, a dopamine receptor antagonist, elicits a rapid increase in plasma aldosterone concentration (PA)' that cannot be explained by simultaneous increases of any of the known stimuli of aldosterone secretion (1) (2) (3) (4) (5) . Furthermore, dopamine can diminish the aldosterone response to angiotensin II in bovine adrenal cells (6) . Patients with primary aldosteronism can be divided into those with aldosterone-producing adenoma and those with bilateral zona glomerulosa hyperplasia (ZGHP). Patients with ZGHP, unlike patients with aldosterone-producing adenoma, usually retain the regulatory mechanisms that decrease aldo-sterone secretion with sodium loading and increase aldosterone secretion with sodium depletion, though these mechanisms are less sensitive to changes in sodium status (7) . In addition, these patients have an enhanced aldosterone response to angiotensin II (8, 9) and to ACTH (10) . Recently, dopamine infusion has been shown to decrease aldosterone production (11) in some patients with aldosterone-producing adenoma, whereas plasma aldosterone concentration does not fall during dopamine infusion in normal subjects (2, 4) . Tonic dopaminergic inhibition of aldosterone secretion has thus been suggested (2, 4) . The influence of dopaminergic mechanisms upon aldosterone secretion in patients with ZGHP would be of great interest, as a defect in the dopaminergic mechanism would be expected to enhance aldosterone secretion. Additional interest in the evaluation of this dopaminergic mechanism has been provided by a recent report suggesting that dopamine decreases the sensitivity of aldosterone secretion in response to angiotensin II (12) . The following study was performed in patients with ZGHP to evaluate the effect of dopamine receptor stimulation with bromocriptine and dopamine and of dopamine receptor antagonism with metoclopramide. Other patients with low-renin hypertension and normal aldosterone suppression with sodium loading, normal-renin hypertension, and aldosterone-producing adenoma were similarly studied for comparison.
METHODS
Secondary forms of hypertension other than primary aldosteronism were ruled out by history, physical examination, blood chemistry studies using an automated multiple analysis system (SMA-12 or SMA-24), urinalysis, urinary metanephrine, and rapid sequence intravenous pyelogram or renal scan. Renin classification was initially performed with plasma renin activity (PRA) response to 2 h of ambulation (13) or with the intravenous furosemide test (14) . Those patients who appeared to have low-renin hypertension after this testing were evaluated further by determining supine and ambulatory PRA after receiving a 10-meq sodium diet for 6 d2 or by determining ambulatory PRA after diuretic administration (13) after ACTH administration in the initial eight patients studied to determine the optimal time of blood sampling. PA usually was slightly higher in the 15-min sample, whereas plasma cortisol was essentially the same in both (Table II) .
For this reason, sampling 15 min after ACTH administration was adopted for the remaining patients. In addition, plasma dopamine concentrations were determined (19) PA, plasma aldosterone after 2 h of ambulation and after 4 h of supine posture with infusion of 2,000 ml normal saline (500 ml/h); Aldo, aldosterone; THAldo, tetrahydroaldosterone.
RESULTS during the base-line phase and on the day of bromocriptine administration are presented in Table III . The The average age, weight, PA, cortisol, PRA, and po-data of the two patients with aldosterone-producing tassium concentrations (0730-1000) of the patients adenoma have been excluded from Tables III and IV n, number of patients studied. (Table III, _ADOPAMINE -/Kg/r 11 12-4 F 2 0800 1000 TIME OF DAY 1200 a lesser, though significant (P < 0.01) fall in PA during dopamine infusion in patients with low-renin hypertension with normal aldosterone suppression (Table  III, Fig. 2 ), whereas patients with normal-renin hypertension had no change in PA with dopamine infusion (Table III, Fig. 3 ). For unknown reasons, the 0800 average PA was slightly lower on the day of dopamine infusion that during the base line. When this 0800 PA was utilized for statistical comparison by paired t test of the 0830-1000 PA values during dopamine infusion, there was also a significant (P < 0.05) suppression in the ZGHP group, but not in the group with low-renin hypertension with normal aldosterone suppression with sodium loading. However, the paired comparisons to the appropriate base-line times appear more valid since this provides for known circadian variations or minor stresses in the testing procedure that might influence PA.
The changes in PA and plasma cortisol with ACTH administered at 1000, 1030, and 1100 are presented in Table IV and Figs. 1-4 and 8. Patients with ZGHP had an enhanced (P < 0.05) increase in PA with ACTH administration (Fig. 4) . There was no significant change in the dose response to ACTH with bromocriptine administration or dopamine infusion (Figs. 1-3 tients with ZGHP and low-renin patients with normal aldosterone suppression had greater (P < 0.05) increases than did normal-renin patients (Fig. 7) . These PA changes did not appear to result from PRA or ACTH stimulation (Table V) .
Two patients with aldosterone-producing adenoma were similarly studied (Fig. 8) Figs. 5 and 6 ). The first patient increased urine volume to 940 ml/h and urinary sodium to 88 meq/h, whereas the second patient increased urinary volume to 572 ml/h and urinary sodium to 64.6 meq/h. Thus, even though these two patients had no PA suppression, they had prominent diuresis and natriuresis with do- with dopamnine infusion is compatible with either a cretion, then a primary loss of this mechanism would primary or secondary phenomenon. If a primary ad-enhance aldosterone secretion. Dopamine infusion renal mechanism is responsible for decreasing aldoste-would thus restore the defective dopaminergic mechrone secretion either directly or indirectly by inhib-anism and would cause PA to fall. However, the apiting the effects of known stimuli of aldosterone se-parent defective adrenal dopaminergic mechanism might result as a secondary phenomenon. Urinary dopamine excretion increases with sodium loading and decreases with sodium depletion (20, 21) . If the adrenal dopaminergic mechanism responds similarly to changes in sodium balance, then the influence of the mechanism on aldosterone secretion would tend to decrease with sodium depletion. Aldosterone secretion is enhanced in patients with ZGHP in response to angiotensin 11 (8, 9) and ACTH (10) similar to that of normal individuals consuming a low-sodium diet (10) . It appears that the aldosterone secretory response may be fixed in a "low-sodium" state for unknown reasons. The diminished dopaminergic influence on aldosterone secretion may be secondary to a primary adrenal alteration that fixes the zona glomerulosa in this lowsodium state. Dopamine infusion might thus be expected to diminish aldosterone secretion in these patients. An alternative possibility for a secondary phenomenon is that a presently undefined stimulus for aldosterone secretion is regulated by a dopaminergic mechanism. An attractive candidate is the recently described aldosterone-stimulating glycoprotein, which has been reported to be present in increased amounts in the urine of patients with ZGHP (8, 22, 23 in normal-renin hypertensives or in normal subjects, who would have more substantial circulating levels of angiotensin II. These data imply that angiotensin II is not regulating aldosterone secretion in a major way in patients with low-renin hypertension. Aldosterone regulation in these patients would appear to be influenced, in a major way, either primarily or secondarily by a dopaminergic mechanism.
A further finding of interest was the lack of influence of bromocriptine administration on PA in any of the groups studied. Some investigators have noted a diminished aldosterone response to angiotensin II and diuretic administration in normal subjects or hypertensive patients administered bromocriptine chronically (24, 25) , whereas these responses were not blocked with 1 d of bromocriptine therapy (3). A consistent finding has been a lack of effect of bromocriptine on basal PA (3, 24, 25) . Though bromocriptine is a known dopaminergic agonist, its inability to influence aldosterone secretion would imply that it stimulates a different type of dopamine receptor than the adrenal dopamine receptor stimulated by dopamine infusion and blocked by metoclopramide. Considerable heterogeneity in dopamine receptors has been recognized (26) (27) (28) . Further characterization of the adrenal dopamine receptor, which influences aldosterone secretion, might be quite helpful in developing more specific therapeutic agents for the treatment of ZGHP.
The prompt rise in PA with metoclopramide administration in patients with ZGHP as well as in other low-renin patients implies that there is not a complete loss of the dopaminergic mechanism suppressing aldosterone secretion. Other investigators have also noted an increase in PA after metoclopramide administration to patients with primary aldosteronism (5). The enhanced PA rise in patients with ZGHP is difficult to interpret. Since zona glomerulosa mass would be expected to be considerably increased in these patients in comparison to patients with normal-renin hypertension, there might be a moderate loss of the dopaminergic mechanism in the zona glomerulosa, but the increased mass of these cells might still provide a net enhanced aldosterone secretion in response to metoclopramide. This would appear to be the most likely explanation for the findings that we observed, though further studies are required to clarify these questions.
The marked increase in urinary volume and sodium excretion with dopamine infusion in patients with primary aldosteronism is of interest. This enhanced diuresis and natriuresis may reflect the response with volume-expanded hypertension to dopamine infusion. However, another interesting possibility, is that both adrenal and renal dopaminergic mechanisms are defective. A renal dopamine receptor capable of enhancing natriuresis has been identified (29, 30) . If both adrenal and renal dopaminergic mechanisms were defective, sodium retention would be favored even more, and marked amplification in the level of hypertension would be expected. Bilateral adrenalectomy in patients with ZGHP has usually not reversed the hypertension (31, 32) . This finding is somewhat difficult to interpret since it is quite likely that bilateral adrenalectomy has been reserved for only those patients with more severe hypertension. These patients might then have initiated secondary mechanisms that would continue the hypertension and be analogous to the experimental counterpart of metacorticoid hypertension (33) . There is also some evidence that a dopaminergic mechanism unrelated to aldosterone secretion may be etiologic in the hypertension of the spontaneous hypertensive rat, since both bromocriptine and L-dopa administration reverse the hypertension in this model, whereas they cause no significant fall in blood pressure in normal controls (34, 35) . Further studies would be helpful in clarifying the relationship between adrenal, renal, and systemic dopaminergic mechanisms, all of which might influence blood pressure regulation.
Suppression of PA by dopamine infusion in lowrenin patients with normal aldosterone suppression with sodium loading is of interest since it suggests a certain pathophysiological kinship of the smaller group of ZGHP with the larger low-renin group. However, these patients did not have a hypersensitive aldosterone response to ACTH, as did patients with ZGHP. These data confirm our earlier failure to find enhanced aldosterone response to ACTH in the majority of patients with low-renin "essential" hypertension in comparison with normal subjects (10) . However, in this earlier report (10) we noted that a subgroup of these low-renin patients had aldosterone responsiveness to ACTH indistinguishable to that of patients with primary aldosteronism due to either ZGHP or aldosterone-producing adenoma, suggesting that more complete evaluation of aldosterone regulation in low-renin patients might identify patients with subtle ZGHP more correctly. Nonetheless, as discussed earlier, since the zona glomerulosa mass in these low-renin patients with normal aldosterone suppression might be smaller than in patients with ZGHP, the zona glomerulosa sensitivity to ACTH might be identical to that in ZGHP, but there still might not be an enhanced rise in PA. We noted that two of the five low-renin patients with normal aldosterone suppression had 0730-1000 PA levels part of the time that overlapped with the lower range of PA values in some of the patients with ZGHP. Thus, it is possible that some of these patients have even milder forms of ZGHP. Since there is evidence that patients with ZGHP have a hypertensinogenic mechanism in addition to the abnormality in aldosterone regulation (31, 32) , then a different balance of these two mechanisms might result in a patient being classified as ZGHP or as low-renin hypertension with normal aldosterone suppression. We have utilized abnormal aldosterone suppression in response to sodium loading as a means of classifying low-renin patients as having ZGHP. However, the accuracy of a means of separating these patients from other types of low-renin hypertensives will remain unknown until more is understood about the etiology of ZGHP. However, it would appear that all of these low-renin patients are not variants of essential hypertension, since there was no suppression of PA with dopamine infusion in patients with normal-renin hypertension. Further studies are required to clarify the importance of dopaminergic mechanisms in regulating aldosterone secretion and in blood pressure control.
